Senetek Expects To License Zeatin Technology In 12 To 18 Months
This article was originally published in The Rose Sheet
Executive Summary
Healthcare technology company Senetek expects to have a new patented anti-aging compound, Zeatin, ready to license to skin care manufacturers within the next 12 to 18 months, Chairman and CEO Frank Massino said, cautioning the timeframe will be directed by the timing of upcoming pre-clinical and clinical efficacy studies